Yangxia Wang obtained her bachelor's degree from Xiangya School of Medicine at Central South University, Changsha, China. She then pursued further studies at the University of Ottawa, Canada, where she worked in Dr. William Stanford's laboratory. During this period, Yangxia made significant progress on a challenging project that utilized induced pluripotent stem cells to model Tuberous Sclerosis Complex and Lymphangioleiomyomatosis. Concurrently, she volunteered at the Ottawa Heart Institute, contributing to data entry and analysis.

Subsequently, Yangxia transitioned to clinical diagnostic work at the First Affiliated Hospital of Zhengzhou University, China, where she obtained a master's degree. In 2022, she was awarded a Provincial Health Commission Co-construction Project Fund, an advanced individual award, and recognition as an outpatient service model worker. Yangxia's passion lies in clinical diagnostic biomarkers, particularly those related to early-stage disease detection in blood samples, encompassing both basic research and clinical translation.

Her research on exosomal circRNAs has been published in Molecular Cancer, and she has served as a peer reviewer for multiple circRNA-related articles in the Journal of Experimental and Clinical Cancer Research. Driven by a desire to delve deeper into the realm of exosomal blood biomarkers, Yangxia joined the Bitan laboratory where she is primarily involved in research on blood biomarkers for various neurodegenerative diseases.

M.S. in Clinical Laboratory Diagnostics - Zhengzhou University, Zhengzhou, Henan, China.

B.S. in Laboratory Medicine - Central South University, Changsha, Hunan, China.

  1. Qu L, She P, Wang Y, Liu F, Zhang D, Chen L, Luo Z, Xu H, Qi Y, Wu Y: Effects of norspermidine on Pseudomonas aeruginosa biofilm formation and eradication. MicrobiologyOpen 2016, 5:402-412.
  2. She P, Chen L, Qi Y, Xu H, Liu Y, Wang Y, Luo Z, Wu Y: Effects of human serum and apo-Transferrin on Staphylococcus epidermidis RP62A biofilm formation. MicrobiologyOpen 2016, 5:957-966.
  3. She P, Wang Y, Luo Z, Chen L, Tan R, Wang Y, Wu Y: Meloxicam inhibits biofilm formation and enhances antimicrobial agents efficacy by Pseudomonas aeruginosa. MicrobiologyOpen 2018, 7.
  4. Sun T, Jiao L, Wang Y, Yu Y, Ming L: SIRT1 induces epithelial-mesenchymal transition by promoting autophagic degradation of E-cadherin in melanoma cells. Cell Death Dis 2018, 9:136.
  5. Ming L, Wang Y, Lu W, Sun T: A Mutational Analysis of GJB2, SLC26A4, MT-RNA1, and GJB3 in Children with Nonsyndromic Hearing Loss in the Henan Province of China. Genet Test Mol Biomarkers 2019, 23:51-56.
  6. Wang Y, Liu J, Ma J, Sun T, Zhou Q, Wang W, Wang G, Wu P, Wang H, Jiang L, et al: Exosomal circRNAs: biogenesis, effect and application in human diseases. Mol Cancer 2019, 18:116.
  7. She P, Liu Y, Wang Y, Tan F, Luo Z, Wu Y: Antibiofilm efficacy of the gold compound auranofin on dual species biofilms of Staphylococcus aureus and Candida sp. J Appl Microbiol 2020, 128:88-101.
  8. She P, Wang Y, Li Y, Zhou L, Li S, Zeng X, Liu Y, Xu L, Wu Y: Drug Repurposing: In vitro and in vivo Antimicrobial and Antibiofilm Effects of Bithionol Against Enterococcus faecalis and Enterococcus faecium. Front Microbiol 2021, 12:579806.
  9. Zhao Z, Wan J, Guo M, Yang Z, Li Z, Wang Y, Ming L: Long non-coding RNA LINC01559 exerts oncogenic role via enhancing autophagy in lung adenocarcinoma. Cancer Cell Int 2021, 21:624.
  10. Zheng J, Zhao Z, Wan J, Guo M, Wang Y, Yang Z, Li Z, Ming L, Qin Z: N-6 methylation-related lncRNA is potential signature in lung adenocarcinoma and influences tumor microenvironment. J Clin Lab Anal 2021, 35:e23951.
  11. Zhao Z, Wan J, Guo M, Wang Y, Yang Z, Zhou F, Li Z, Ming L: Expression and prognostic significance of m6A-related genes in TP53-mutant non-small-cell lung cancer. J Clin Lab Anal 2022, 36:e24118.

2022 - Provincial Health Commission Co-construction Project Fund Award, "Detection of a Novel Circulating Exosomal Biomarker circHERC1 for Esophageal Cancer Based on Microfluidic Immunoassay Technology". $20,000.